L
Leap Therapeutics
LPTX
2.12000
USD
-0.02
(-0.93%)
مغلق
حجم التداول
4,516
الربح لكل سهم
0
العائد الربحي
0
P/E
-4
حجم السوق
141,961,161
العنوان: Leap Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .